السوق العالمية للبدائل الحيوية لدواء أداليموماب - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ADALIMUMAB BIOSIMILAR MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL ADALIMUMAB BIOSIMILAR MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY MODELING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL ADALIMUMAB BIOSIMILAR MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 MERGERS AND ACQUISITIONS

10.8 FUTURE OUTLOOK

11 EPIDEMIOLOGY

11.1 INCIDENCE OF ALL BY GENDER

11.2 TREATMENT RATE

11.3 MORTALITY RATE

11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

11.5 PATIENT TREATMENT SUCCESS RATES

12 REGULATORY COMPLIANCE

12.1 REGULATORY AUTHORITIES

12.2 REGULATORY CLASSIFICATIONS

12.2.1 CLASS I

12.2.2 CLASS II

12.2.3 CLASS III

12.3 REGULATORY SUBMISSIONS

12.4 INTERNATIONAL HARMONIZATION

12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

12.6 REGULATORY CHALLENGES AND STRATEGIES

13 PIPELINE ANALYSIS

13.1 CLINICAL TRIALS AND PHASE ANALYSIS

13.2 DRUG THERAPY PIPELINE

13.3 PHASE III CANDIDATES

13.4 PHASE II CANDIDATES

13.5 PHASE I CANDIDATES

13.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR ADALIMUMAB BIOSIMILAR MARKET

Company Name Product Name

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR ADALIMUMAB BIOSIMILAR MARKET

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved but Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR ADALIMUMAB BIOSIMILAR MARKET

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR ADALIMUMAB BIOSIMILAR MARKET

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR ADALIMUMAB BIOSIMILAR MARKET

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

14 REIMBURSEMENT FRAMEWORK

15 OPPUTUNITY MAP ANALYSIS

16 VALUE CHAIN ANALYSIS

17 HEALTHCARE ECONOMY

17.1 HEALTHCARE EXPENDITURE

17.2 CAPITAL EXPENDITURE

17.3 CAPEX TRENDS

17.4 CAPEX ALLOCATION

17.5 FUNDING SOURCES

17.6 INDUSTRY BENCHMARKS

17.7 GDP RATION IN OVERALL GDP

17.8 HEALTHCARE SYSTEM STRUCTURE

17.9 GOVERNMENT POLICIES

17.1 ECONOMIC DEVELOPMENT

18 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY PRODUCT

18.1 OVERVIEW

18.2 MARKETED/APPROVED

18.2.1 EXEMPTIA

18.2.1.1. MARKET VALUE (USD MN)

18.2.1.2. MARKET VOLUME (STANDARD UNIT)

18.2.1.3. AVERAGE SELLING PRICE (USD)

18.2.2 ADALIREL

18.2.2.1. MARKET VALUE (USD MN)

18.2.2.2. MARKET VOLUME (STANDARD UNIT)

18.2.2.3. AVERAGE SELLING PRICE (USD)

18.2.3 CIPLEUMAB

18.2.3.1. MARKET VALUE (USD MN)

18.2.3.2. MARKET VOLUME (STANDARD UNIT)

18.2.3.3. AVERAGE SELLING PRICE (USD)

18.2.4 AMJEVITA

18.2.4.1. MARKET VALUE (USD MN)

18.2.4.2. MARKET VOLUME (STANDARD UNIT)

18.2.4.3. AVERAGE SELLING PRICE (USD)

18.2.5 YUFLYMA (ADALIMUMAB-AATY)

18.2.5.1. MARKET VALUE (USD MN)

18.2.5.2. MARKET VOLUME (STANDARD UNIT)

18.2.5.3. AVERAGE SELLING PRICE (USD)

18.2.6 CYLTEZO (ADALIMUMAB-ADBM)

18.2.6.1. MARKET VALUE (USD MN)

18.2.6.2. MARKET VOLUME (STANDARD UNIT)

18.2.6.3. AVERAGE SELLING PRICE (USD)

18.2.7 HADLIMA (ADALIMUMAB-BWWD)

18.2.7.1. MARKET VALUE (USD MN)

18.2.7.2. MARKET VOLUME (STANDARD UNIT)

18.2.7.3. AVERAGE SELLING PRICE (USD)

18.2.8 SIMLANDI (ADALIMUMAB-RYVK)

18.2.8.1. MARKET VALUE (USD MN)

18.2.8.2. MARKET VOLUME (STANDARD UNIT)

18.2.8.3. AVERAGE SELLING PRICE (USD)

18.2.9 ABRILADA (ADALIMUMAB-AFZB)

18.2.9.1. MARKET VALUE (USD MN)

18.2.9.2. MARKET VOLUME (STANDARD UNIT)

18.2.9.3. AVERAGE SELLING PRICE (USD)

18.2.10 HULIO (ADALIMUMAB-FKJP)

18.2.10.1. MARKET VALUE (USD MN)

18.2.10.2. MARKET VOLUME (STANDARD UNIT)

18.2.10.3. AVERAGE SELLING PRICE (USD)

18.2.11 IDACIO (ADALIMUMAB-AACF)

18.2.11.1. MARKET VALUE (USD MN)

18.2.11.2. MARKET VOLUME (STANDARD UNIT)

18.2.11.3. AVERAGE SELLING PRICE (USD)

18.2.12 HYRIMOZ (ADALIMUMAB-ADAZ)

18.2.12.1. MARKET VALUE (USD MN)

18.2.12.2. MARKET VOLUME (STANDARD UNIT)

18.2.12.3. AVERAGE SELLING PRICE (USD)

18.2.13 YUSIMRY (ADALIMUMAB-AQVH)

18.2.13.1. MARKET VALUE (USD MN)

18.2.13.2. MARKET VOLUME (STANDARD UNIT)

18.2.13.3. AVERAGE SELLING PRICE (USD)

18.2.14 IMRALDI (ADALIMUMAB)

18.2.14.1. MARKET VALUE (USD MN)

18.2.14.2. MARKET VOLUME (STANDARD UNIT)

18.2.14.3. AVERAGE SELLING PRICE (USD)

18.2.15 QLETLI

18.2.15.1. MARKET VALUE (USD MN)

18.2.15.2. MARKET VOLUME (STANDARD UNIT)

18.2.15.3. AVERAGE SELLING PRICE (USD)

18.2.16 XELENKA

18.2.16.1. MARKET VALUE (USD MN)

18.2.16.2. MARKET VOLUME (STANDARD UNIT)

18.2.16.3. AVERAGE SELLING PRICE (USD)

18.2.17 SULINNO

18.2.17.1. MARKET VALUE (USD MN)

18.2.17.2. MARKET VOLUME (STANDARD UNIT)

18.2.17.3. AVERAGE SELLING PRICE (USD)

18.2.18 OTHERS

18.3 PIPELINE

18.3.1 BCD-057

18.3.2 M923

18.3.3 CINNORA

18.3.4 HS016

18.3.5 HLX03

18.3.6 PBP1502

18.3.7 ONS-3010

18.3.8 OTHERS

19 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY FORMS

19.1 OVERVIEW

19.2 PREFILLED SYRINGES

19.2.1 10 MG

19.2.2 20 MG

19.2.3 40 MG

19.2.4 80 MG

19.3 PREFILLED PEN

19.4 AUTOINJECTOR PENS

19.4.1 CLICK AUTOINJECTOR

19.4.2 PUSH AUTOINJECTOR

19.5 VIALS

19.6 OTHERS

20 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY INDICATION

20.1 OVERVIEW

20.2 RHEUMATOID ARTHRITIS

20.2.1 MARKETED/APPROVED

20.2.2 PIPELINE

20.3 JUVENILE IDIOPATHIC ARTHRITIS

20.3.1 MARKETED/APPROVED

20.3.2 PIPELINE

20.4 PSORIATIC ARTHRITIS

20.4.1 MARKETED/APPROVED

20.4.2 PIPELINE

20.5 ANKYLOSING SPONDYLITIS

20.5.1 MARKETED/APPROVED

20.5.2 PIPELINE

20.6 CROHN’S DISEASE

20.6.1 MARKETED/APPROVED

20.6.2 PIPELINE

20.7 CHRONIC PLAQUE PSORIASIS

20.7.1 MARKETED/APPROVED

20.7.2 PIPELINE

20.8 ULCERATIVE COLITIS

20.8.1 MARKETED/APPROVED

20.8.2 PIPELINE

20.9 HIDRADENITIS SUPPURATIVA

20.9.1 MARKETED/APPROVED

20.9.2 PIPELINE

20.1 NON-INFECTIOUS INTERMEDIATE

20.10.1 MARKETED/APPROVED

20.10.2 PIPELINE

20.11 OTHERS

21 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY DOSAGE STRENGTH

21.1 OVERVIEW

21.2 40MG/0.4MLG

21.3 80MG/0.8MLG

21.4 20MG/0.2MLG

21.5 10MG/0.1MLG

21.6 OTHERS

22 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, ROUTE OF ADMINISTRATION

22.1 OVERVIEW

22.2 INTRAVENEOUS

22.3 SUBCUTANEOUS

22.4 OTHERS

23 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY POPULATION TYPE

23.1 OVERVIEW

23.2 PEDIATRIC

23.3 ADULTS

23.4 GERIATRIC

24 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY GENDER

24.1 OVERVIEW

24.2 MALE

24.2.1 PEDIATRIC

24.2.2 ADULTS

24.2.3 GERIATRIC

24.3 FEMALE

24.3.1 PEDIATRIC

24.3.2 ADULTS

24.3.3 GERIATRIC

25 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY END USER

25.1 OVERVIEW

25.2 HOSPITALS

25.2.1 PUBLIC

25.2.2 PRIVATE

25.3 SPECIALTY CLINICS

25.4 HOME HEALTHCARE

25.5 ACADEMIC AND RESEARCH INSTITUTE

25.6 OTHERS

26 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY DISTRIBUTION CHANNEL

26.1 OVERVIEW

26.2 DIRECT TENDER

26.3 RETAIL SALES

26.3.1 HOSPITAL PHARMACIES

26.3.2 DRUG STORES

26.3.3 PHARMACY CHAINS

26.3.4 ONLINE PHARMACIES

26.3.4.1. E-PHARMACY COMPANIES

26.3.4.2. COMPANY OWNED E-PHARMACY

26.4 OTHERS

27 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, BY GEOGRAPHY

GLOBAL ADALIMUMAB BIOSIMILAR MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

27.1 NORTH AMERICA

27.1.1 U.S.

27.1.2 CANADA

27.1.3 MEXICO

27.1.4 DOMINICAN REPUBLIC

27.1.5 JAMAICA

27.1.6 PANAMA

27.2 EUROPE

27.2.1 GERMANY

27.2.2 FRANCE

27.2.3 U.K.

27.2.4 HUNGARY

27.2.5 LITHUANIA

27.2.6 AUSTRIA

27.2.7 IRELAND

27.2.8 NORWAY

27.2.9 POLAND

27.2.10 ITALY

27.2.11 SPAIN

27.2.12 RUSSIA

27.2.13 TURKEY

27.2.14 NETHERLANDS

27.2.15 SWITZERLAND

27.2.16 REST OF EUROPE

27.3 ASIA-PACIFIC

27.3.1 JAPAN

27.3.2 CHINA

27.3.3 TAIWAN

27.3.4 SOUTH KOREA

27.3.5 INDIA

27.3.6 AUSTRALIA

27.3.7 SINGAPORE

27.3.8 THAILAND

27.3.9 MALAYSIA

27.3.10 INDONESIA

27.3.11 PHILIPPINES

27.3.12 VIETNAM

27.3.13 REST OF ASIA-PACIFIC

27.4 SOUTH AMERICA

27.4.1 BRAZIL

27.4.2 ECUADOR

27.4.3 CHILE

27.4.4 COLOMBIA

27.4.5 VENEZUELA

27.4.6 ARGENTINA

27.4.7 PERU

27.4.8 CURAÇAO

27.4.9 PARAGUAY

27.4.10 URUGUAY

27.4.11 TRINIDAD AND TOBAGO

27.4.12 REST OF SOUTH AMERICA

27.5 MIDDLE EAST AND AFRICA

27.5.1 SOUTH AFRICA

27.5.2 SAUDI ARABIA

27.5.3 UAE

27.5.4 EGYPT

27.5.5 KUWAIT

27.5.6 ISRAEL

27.5.7 BOLIVIA

27.5.8 REST OF MIDDLE EAST AND AFRICA

27.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

28 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, SWOT AND DBMR ANALYSIS

29 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, COMPANY LANDSCAPE

29.1 COMPANY SHARE ANALYSIS: GLOBAL

29.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

29.3 COMPANY SHARE ANALYSIS: EUROPE

29.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

29.5 MERGERS & ACQUISITIONS

29.6 NEW PRODUCT DEVELOPMENT & APPROVALS

29.7 EXPANSIONS

29.8 REGULATORY CHANGES

29.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

30 GLOBAL ADALIMUMAB BIOSIMILAR MARKET, COMPANY PROFILE

30.1 MARKETED COMPANY

30.1.1 AMGEN INC.

30.1.1.1. COMPANY OVERVIEW

30.1.1.2. REVENUE ANALYSIS

30.1.1.3. GEOGRAPHIC PRESENCE

30.1.1.4. PRODUCT PORTFOLIO

30.1.1.5. RECENT DEVELOPMENTS

30.1.2 BOEHRINGER INGELHEIM GMBH

30.1.2.1. COMPANY OVERVIEW

30.1.2.2. REVENUE ANALYSIS

30.1.2.3. GEOGRAPHIC PRESENCE

30.1.2.4. PRODUCT PORTFOLIO

30.1.2.5. RECENT DEVELOPMENTS

30.1.3 SANDOZ INC. (NOVARTIS AG)

30.1.3.1. COMPANY OVERVIEW

30.1.3.2. REVENUE ANALYSIS

30.1.3.3. GEOGRAPHIC PRESENCE

30.1.3.4. PRODUCT PORTFOLIO

30.1.3.5. RECENT DEVELOPMENTS

30.1.4 BIOGEN

30.1.4.1. COMPANY OVERVIEW

30.1.4.2. REVENUE ANALYSIS

30.1.4.3. GEOGRAPHIC PRESENCE

30.1.4.4. PRODUCT PORTFOLIO

30.1.4.5. RECENT DEVELOPMENTS

30.1.5 ORGANON GROUP OF COMPANIES

30.1.5.1. COMPANY OVERVIEW

30.1.5.2. REVENUE ANALYSIS

30.1.5.3. GEOGRAPHIC PRESENCE

30.1.5.4. PRODUCT PORTFOLIO

30.1.5.5. RECENT DEVELOPMENTS

30.1.6 FRESENIUS KABI USA, LLC.

30.1.6.1. COMPANY OVERVIEW

30.1.6.2. REVENUE ANALYSIS

30.1.6.3. GEOGRAPHIC PRESENCE

30.1.6.4. PRODUCT PORTFOLIO

30.1.6.5. RECENT DEVELOPMENTS

30.1.7 CELLTRION USA INC.

30.1.7.1. COMPANY OVERVIEW

30.1.7.2. REVENUE ANALYSIS

30.1.7.3. GEOGRAPHIC PRESENCE

30.1.7.4. PRODUCT PORTFOLIO

30.1.7.5. RECENT DEVELOPMENTS

30.1.8 BIOCON BIOLOGICS INC.

30.1.8.1. COMPANY OVERVIEW

30.1.8.2. REVENUE ANALYSIS

30.1.8.3. GEOGRAPHIC PRESENCE

30.1.8.4. PRODUCT PORTFOLIO

30.1.8.5. RECENT DEVELOPMENTS

30.1.9 TEVA PHARMACEUTICALS, INC. + ALVOTECH USA INC.,

30.1.9.1. COMPANY OVERVIEW

30.1.9.2. REVENUE ANALYSIS

30.1.9.3. GEOGRAPHIC PRESENCE

30.1.9.4. PRODUCT PORTFOLIO

30.1.9.5. RECENT DEVELOPMENTS

30.1.10 COHERUS BIOSCIENCES INC.

30.1.10.1. COMPANY OVERVIEW

30.1.10.2. REVENUE ANALYSIS

30.1.10.3. GEOGRAPHIC PRESENCE

30.1.10.4. PRODUCT PORTFOLIO

30.1.10.5. RECENT DEVELOPMENTS

30.1.11 CATALENT INDIANA, LLC

30.1.11.1. COMPANY OVERVIEW

30.1.11.2. REVENUE ANALYSIS

30.1.11.3. GEOGRAPHIC PRESENCE

30.1.11.4. PRODUCT PORTFOLIO

30.1.11.5. RECENT DEVELOPMENTS

30.1.12 SAMSUNG BIOEPIS

30.1.12.1. COMPANY OVERVIEW

30.1.12.2. REVENUE ANALYSIS

30.1.12.3. GEOGRAPHIC PRESENCE

30.1.12.4. PRODUCT PORTFOLIO

30.1.12.5. RECENT DEVELOPMENTS

30.1.13 PFIZER INC.

30.1.13.1. COMPANY OVERVIEW

30.1.13.2. REVENUE ANALYSIS

30.1.13.3. GEOGRAPHIC PRESENCE

30.1.13.4. PRODUCT PORTFOLIO

30.1.13.5. RECENT DEVELOPMENTS

30.1.14 MYLAN N.V. AND FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.

30.1.14.1. COMPANY OVERVIEW

30.1.14.2. REVENUE ANALYSIS

30.1.14.3. GEOGRAPHIC PRESENCE

30.1.14.4. PRODUCT PORTFOLIO

30.1.14.5. RECENT DEVELOPMENTS

30.1.15 INNOVENT BIOLOGICS, INC.

30.1.15.1. COMPANY OVERVIEW

30.1.15.2. REVENUE ANALYSIS

30.1.15.3. GEOGRAPHIC PRESENCE

30.1.15.4. PRODUCT PORTFOLIO

30.1.15.5. RECENT DEVELOPMENTS

30.1.16 RELIANCE LIFE SCIENCES

30.1.16.1. COMPANY OVERVIEW

30.1.16.2. REVENUE ANALYSIS

30.1.16.3. GEOGRAPHIC PRESENCE

30.1.16.4. PRODUCT PORTFOLIO

30.1.16.5. RECENT DEVELOPMENTS

30.1.17 HETERO

30.1.17.1. COMPANY OVERVIEW

30.1.17.2. REVENUE ANALYSIS

30.1.17.3. GEOGRAPHIC PRESENCE

30.1.17.4. PRODUCT PORTFOLIO

30.1.17.5. RECENT DEVELOPMENTS

30.1.18 TORRENT PHARMA

30.1.18.1. COMPANY OVERVIEW

30.1.18.2. REVENUE ANALYSIS

30.1.18.3. GEOGRAPHIC PRESENCE

30.1.18.4. PRODUCT PORTFOLIO

30.1.18.5. RECENT DEVELOPMENTS

30.1.19 SHANGHAI JUNSHI BIOSCIENCES CO LTD.

30.1.19.1. COMPANY OVERVIEW

30.1.19.2. REVENUE ANALYSIS

30.1.19.3. GEOGRAPHIC PRESENCE

30.1.19.4. PRODUCT PORTFOLIO

30.1.19.5. RECENT DEVELOPMENTS

30.1.20 ZYDUS LIFESCIENCES LTD.

30.1.20.1. COMPANY OVERVIEW

30.1.20.2. REVENUE ANALYSIS

30.1.20.3. GEOGRAPHIC PRESENCE

30.1.20.4. PRODUCT PORTFOLIO

30.1.20.5. RECENT DEVELOPMENTS

30.1.21 BIOXPRESS THERAPEUTICS SA

30.1.21.1. COMPANY OVERVIEW

30.1.21.2. REVENUE ANALYSIS

30.1.21.3. GEOGRAPHIC PRESENCE

30.1.21.4. PRODUCT PORTFOLIO

30.1.21.5. RECENT DEVELOPMENTS

30.1.22 BIO-THERA PHARMACEUTICALS CO., LTD.

30.1.22.1. COMPANY OVERVIEW

30.1.22.2. REVENUE ANALYSIS

30.1.22.3. GEOGRAPHIC PRESENCE

30.1.22.4. PRODUCT PORTFOLIO

30.1.22.5. RECENT DEVELOPMENTS

30.1.23 HISUN USA, INC.

30.1.23.1. COMPANY OVERVIEW

30.1.23.2. REVENUE ANALYSIS

30.1.23.3. GEOGRAPHIC PRESENCE

30.1.23.4. PRODUCT PORTFOLIO

30.1.23.5. RECENT DEVELOPMENTS

30.1.24 LG CHEM, LTD.

30.1.24.1. COMPANY OVERVIEW

30.1.24.2. REVENUE ANALYSIS

30.1.24.3. GEOGRAPHIC PRESENCE

30.1.24.4. PRODUCT PORTFOLIO

30.1.24.5. RECENT DEVELOPMENTS

30.2 PIPELINE

30.2.1 MOMENTA PHARMACEUTICALS, INC.

30.2.1.1. COMPANY OVERVIEW

30.2.1.2. REVENUE ANALYSIS

30.2.1.3. GEOGRAPHIC PRESENCE

30.2.1.4. PRODUCT PORTFOLIO

30.2.1.5. RECENT DEVELOPMENTS

30.2.2 MABXIENCE

30.2.2.1. COMPANY OVERVIEW

30.2.2.2. REVENUE ANALYSIS

30.2.2.3. GEOGRAPHIC PRESENCE

30.2.2.4. PRODUCT PORTFOLIO

30.2.2.5. RECENT DEVELOPMENTS

30.2.3 SHANGHAI HENLIUS BIOTECH, INC.

30.2.3.1. COMPANY OVERVIEW

30.2.3.2. REVENUE ANALYSIS

30.2.3.3. GEOGRAPHIC PRESENCE

30.2.3.4. PRODUCT PORTFOLIO

30.2.3.5. RECENT DEVELOPMENTS

30.2.4 BIOCAD

30.2.4.1. COMPANY OVERVIEW

30.2.4.2. REVENUE ANALYSIS

30.2.4.3. GEOGRAPHIC PRESENCE

30.2.4.4. PRODUCT PORTFOLIO

30.2.4.5. RECENT DEVELOPMENTS

30.2.5 PRESTIGE BIOPHARMA LTD.

30.2.5.1. COMPANY OVERVIEW

30.2.5.2. REVENUE ANALYSIS

30.2.5.3. GEOGRAPHIC PRESENCE

30.2.5.4. PRODUCT PORTFOLIO

30.2.5.5. RECENT DEVELOPMENTS

30.2.6 CINNAGEN CO.

30.2.6.1. COMPANY OVERVIEW

30.2.6.2. REVENUE ANALYSIS

30.2.6.3. GEOGRAPHIC PRESENCE

30.2.6.4. PRODUCT PORTFOLIO

30.2.6.5. RECENT DEVELOPMENTS

30.2.7 PLANTFORM CORPORATION

30.2.7.1. COMPANY OVERVIEW

30.2.7.2. REVENUE ANALYSIS

30.2.7.3. GEOGRAPHIC PRESENCE

30.2.7.4. PRODUCT PORTFOLIO

30.2.7.5. RECENT DEVELOPMENTS

30.2.8 OUTLOOK THERAPEUTICS, INC.

30.2.8.1. COMPANY OVERVIEW

30.2.8.2. REVENUE ANALYSIS

30.2.8.3. GEOGRAPHIC PRESENCE

30.2.8.4. PRODUCT PORTFOLIO

30.2.8.5. RECENT DEVELOPMENTS

30.2.9 NEUCLONE

30.2.9.1. COMPANY OVERVIEW

30.2.9.2. REVENUE ANALYSIS

30.2.9.3. GEOGRAPHIC PRESENCE

30.2.9.4. PRODUCT PORTFOLIO

30.2.9.5. RECENT DEVELOPMENTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

31 RELATED REPORTS

32 CONCLUSION

33 QUESTIONNAIRE

34 ABOUT DATA BRIDGE MARKET RESEARCH